Lyell Immunopharma, Inc. (LYEL) SEC Filings & Earnings Calls

Clinical trial timeline update may indicate delays or progress; no new efficacy/safety data

“Updated timeline on Phase 1/2 trial evaluating LYL273 in metastatic colorectal cancer.”

Increasing net loss and R&D spend may pressure cash runway if pipeline milestones are delayed

“Net loss increased $2.1M YoY due to $4.7M increase in R&D expenses driven by increased clinical trial activity.”

Going concern risk / need for additional capital

“We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.” · word for word

Clinical trial failure risk

“The risk of failure of our product candidates, or any product candidates we acquire, is high.” · word for word

Manufacturing complexity and supply risk

“The manufacturing of cell therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.” · word for word

Competition risk

“We face substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than we do.” · word for word

Tariff / trade policy risk

“Current or future tariffs may result in increased research and development expenses, including with respect to increased costs associated with raw materials, manufacturing equipment, laboratory equipment and research materials and components.” · word for word

Clinical trial failure risk

“The risk of failure of our product candidates, or any product candidates we acquire, is high.” · word for word

Capital need risk

“We anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved product candidates.” · word for word

Manufacturing complexity risk

“The manufacturing of cell therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.” · word for word

Tariff/trade policy risk

“Current or future tariffs may result in increased research and development expenses, including with respect to increased costs associated with raw materials, manufacturing equipment, laboratory equipment and research materials and components.” · word for word

Clinical trial execution risk; pivotal data not expected until mid-2027

“pivotal data expected mid-2027 and BLA submission expected to follow in 2027” · word for word

Dependence on successful clinical outcomes for ronde-cel and LYL273

“PiNACLE pivotal clinical trial evaluating ronde-cel... on track to report additional data in second half of 2026” · word for word

Cash runway limited to Q3 2027; may require additional financing

“expected to provide runway into Q3 2027” · word for word

Net loss increased significantly; cash burn remains high.

“Net loss of $140.7M in Q4 2025; cash runway only into Q2 2027.”

Clinical trial risks: Phase 3 data not yet available; regulatory approval uncertain.

“PiNACLE-H2H trial just commenced; pivotal data expected mid-next year.”

No approved products and history of losses

“We are a late-stage clinical cell therapy company that has incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future.” · word for word

Need for substantial additional capital

“We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.” · word for word

Clinical trial failure risk

“The results of research, nonclinical studies or earlier clinical trials are not necessarily predictive of future results. If clinical trials of our product candidates fail to produce, or continue to produce, positive results or demonstrate satisfactory safety and efficacy, at the appropriate dose level or at all, we may incur additional costs or experience d”

Manufacturing complexity and risk

“The manufacturing of cell therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.” · word for word

Competition from established therapies

“We face substantial competition in a rapidly changing industry, which may result in others discovering, developing or commercializing products before or more successfully than we do.” · word for word

Pre-revenue and significant accumulated deficit

“We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. We had an accumulated deficit of $1.5 billion as of September 30, 2025.” · word for word

Need for additional capital

“We anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved product candidates.” · word for word

Clinical trial and regulatory risk

“The risk of failure of our product candidates, or any product candidates we acquire, is high. The clinical trials and manufacturing of our product candidates... are subject to extensive and rigorous review and regulation.”

Manufacturing complexity and reliance

“The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates.” · word for word

Competition

“We face substantial competition in rapidly changing industries, which may result in others discovering, developing or commercializing products before or more successfully than we do.” · word for word

Clinical trial risk; ronde-cel pivotal data not yet mature

“PiNACLE trial data expected to form basis of BLA submission in 2027”